Singapore - English - HSA (Health Sciences Authority)

seqirus pte. ltd. - influenza virus (sh) a/california/07/2009 (h1n1) pdm09- like strain; influenza virus (sh) a/hong kong/4801/2014 (h3n2) - like strain; influenza virus (sh) b/brisbane/60/2008 - like strain - injection - 15 mcg ha/0.5ml - influenza virus (sh) a/california/07/2009 (h1n1) pdm09- like strain 15 mcg ha/0.5ml; influenza virus (sh) a/hong kong/4801/2014 (h3n2) - like strain 15 mcg ha/0.5ml; influenza virus (sh) b/brisbane/60/2008 - like strain 15 mcg ha/0.5ml

European Union - English - EMA (European Medicines Agency)

seqirus s.r.l.  - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza-a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/turkey/turkey/1/05 (h5n1)-like strain.aflunov should be used in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: monobasic potassium phosphate; water for injections; thiomersal; calcium chloride dihydrate; dibasic sodium phosphate; potassium chloride; sodium chloride; monobasic sodium phosphate - for active immunization against influenza disease caused by influenza subtype viruses and type b viruses contained in the vaccine.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: dibasic sodium phosphate; water for injections; monobasic potassium phosphate; sodium chloride; potassium chloride; calcium chloride dihydrate; monobasic sodium phosphate - for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - influenza virus, quantity: 10000000 ffu - spray, nasal - excipient ingredients: arginine hydrochloride; monosodium glutamate monohydrate; sucrose; monobasic potassium phosphate; gelatin; dibasic potassium phosphate; water for injections - flumist quadrivalent is indicated for the prevention of influenza in children and adolescents from 24 months to less than 18 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - influenza virus haemagglutinin -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - influenza virus haemagglutinin, quantity: 3.75 microgram - injection, suspension - excipient ingredients: water for injections; polysorbate 80; magnesium chloride hexahydrate; sodium chloride; thiomersal; potassium chloride; dibasic sodium phosphate dodecahydrate; octoxinol 10; monobasic potassium phosphate - prophylaxis of influenza in an officially declared pandemic situation. pandemrix h5n1 should be used in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram - injection, suspension - excipient ingredients: aluminium; dibasic sodium phosphate; calcium chloride dihydrate; potassium chloride; thiomersal; monobasic sodium phosphate; monobasic potassium phosphate; sodium chloride - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with australian health authorities' recommendations, taking into account the recommendation of the world health organisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: monobasic potassium phosphate; thiomersal; calcium chloride dihydrate; dibasic sodium phosphate; sodium chloride; potassium chloride; monobasic sodium phosphate; water for injections - indicated for the prevention of influenza caused by influenza virus, types a and b.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -